Not enough data
Andrea S. Blevins Primeau's coverage primarily focuses on cancer care, treatment, and research. Her articles show a strong emphasis on citing data to support her content.
Given this focus, she would likely be interested in pitches that offer access to new or underreported clinical trial results, insights from healthcare professionals involved in cutting-edge cancer treatments or researchers making breakthroughs in the field of oncology.
Her lack of specified geographic focus suggests an openness to international perspectives on these topics. If you have unique data-backed insights related to advancements in cancer treatment, clinical trials, or patient experiences with innovative therapies, it could capture her attention.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Andrea S. Blevins Primeau
Patients who develop acute heart failure (AHF) during hematopoietic stem cell transplantation (HSCT) demonstrated worse outcomes, including longer hospital stays and higher mortality rates, according to a poster presented at the 2026 NCCN Annual Conference.
By: Andrea S. Blevins Primeau
Our easy-to-read fact sheets provide clinicians with reliable information to share with patients and their caregivers.
By: Andrea S. Blevins Primeau
High-dose methotrexate (HD-MTX) treatment after achieving clinical metabolic response (CMR) to R-CHOP resulted in substantial reductions in central nervous system (CNS) relapse among patients with large B-cell lymphomas (LBCLs), according to an analysis of the retrospective CHARTHER study published in the American Journal of Hematology. Patients who received HD-MTX also demonstrated longer progression-free survival (PFS) and overall survival (OS).
By: Andrea S. Blevins Primeau
Some patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) who were positive for minimal residual disease (MRD) after initial treatment demonstrated long-term remission with up to 2 years of azacitidine, according to long-term results from the phase 2 RELAZA2 trial published in the journal Blood. In addition, a subset of patients maintained remission after azacitidine discontinuation.
By: Andrea S. Blevins Primeau
Our easy-to-read fact sheets provide clinicians with reliable information to share with patients and their caregivers. What is Gout?
By: Andrea S. Blevins Primeau
Survivors of childhood acute myeloid leukemia (AML) are at an increased risk of developing chemotherapy-related cognitive impairment (CRCI), including working memory and executive functioning, according to a poster presented at the AACR Annual Meeting 2026.
By: Andrea S. Blevins Primeau
Four novel loci were identified in a multi-ancestry genome-wide association study (GWAS) that conferred an increased risk of developing pediatric acute myeloid leukemia (AML), according to a poster presented at the AACR Annual Meeting 2026.
By: Andrea S. Blevins Primeau
Among pediatric patients with hemophilia A with inhibitors, immune tolerance induction (ITI) alone resulted in shorter time to inhibitor clearance compared with ITI plus emicizumab, according to results from the MOTIVATE study presented at the 2026 ASPHO Conference.
By: Andrea S. Blevins Primeau
NXT007, a next-generation bispecific antibody, demonstrated promising efficacy and safety as prophylaxis among patients with moderate to severe hemophilia A with or without inhibitors, according to results of a phase 1/2 study presented at the 2026 ASPHO Conference.
By: Andrea S. Blevins Primeau
A novel smartphone application has been developed to help patients with hemophilia manage their condition, including taking medication, send appointment reminders, record notes, and provide the ability to communicate and send reports to healthcare providers.
